Expanded carrier screening (ECS) is increasingly offered within assisted reproductive technologies (ART), particularly as a component of donor gamete selection. As genomic testing options rapidly evolve, the complexity of interpreting ECS results presents significant challenges for donor gamete recipients and the healthcare professionals supporting them. At the same time, regulatory frameworks and professional guidelines have not kept pace with these technological developments, resulting in gaps between clinical practice and formal guidance. This paper aims to summarise current practice, highlight emerging issues arising from the integration of ECS into gamete selection, and provide recommendations to facilitate informed decision-making.
No takes yet. Share an insight, caveat, or question.
Shaikly et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: